PRRT2 and myeloid leukemia: The known growth inhibition of the K562 human myelogenous leukemia cell line at nM levels by the prototypic PKC activator PMA (Fig. 2B)30 was used to compare antineoplastic potential, integrating possible differences in drug uptake and PKC activation in vitro.